Keyword: Louisiana

Washington plans to treat tens of thousands of hepatitis C patients on state-purchased health insurance.

Louisiana has proposed a "subscription-based payment model" for hepatitis C drugs it hopes can benefit the state and drugmakers alike.

With federal officials failing to come up with legislation to control drug prices, that task is moving to the states—and so is pharma muscle.

When Louisiana AG Jeff Landry inherited an antitrust lawsuit against Pfizer in 2015, he spotted an opportunity to combat the state’s opioid epidemic.

Gilead Sciences could soon find itself facing yet another challenge, this time from the U.S. government.